Top

Published in:

Open Access 01-12-2018 | Case report

Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report

Authors: Lucas Souto Nacif, Daniel R. Waisberg, Rafael Soares Pinheiro, Fabiana Roberto Lima, Vinicius Rocha-Santos, Wellington Andraus, Luiz Carneiro D’Albuquerque

Published in: Journal of Medical Case Reports | Issue 1/2018

Abstract

Background

There is a worldwide problem of acute liver failure and mortality associated with remaining on the waiting for a liver transplant. In this study, we highlight results published in recent years by leading transplant centers in evaluating imatinib-induced acute liver failure in chronic myeloid leukemia and follow-up in liver transplantation.

Case presentation

A 36-year-old brown-skinned woman (mixed Brazilian race) diagnosed 1 year earlier with chronic myeloid leukemia was started after delivery of a baby and continued for 6 months with imatinib mesylate (selective inhibitor of Bcr-Abl tyrosine kinase), which induced liver failure. We conducted a literature review using the PubMed database for articles published through September 2017, and we demonstrate a role of liver transplant in this situation for imatinib-induced liver failure. We report previously published results and a successful liver transplant after acute liver failure due to imatinib-induced in chronic myeloid leukemia treatment.

Conclusions

We report a case of a successful liver transplant after acute liver failure resulting from imatinib-induced chronic myeloid leukemia treatment. The literature reveals the importance of prompt acute liver failure diagnosis and treatment with liver transplant in selected cases.

Hessheimer AJ, Nacif L, Flores Villalba E, Fondevila C. Liver transplantation for acute liver failure. Cir Esp. 2017;95(4):181–9.CrossRefPubMed

Harding DJ, MacQuillan G, Howman R, de Boer B, Adams L, Mitchell A, Jeffrey G. Successful use of dasatinib after liver transplantation for imatinib-induced fulminant liver failure in chronic myeloid leukemia. J Clin Oncol. 2016;34(11):e97–8.CrossRefPubMed

Talpaz M, Silver R, Druker B, Goldman J, Gambacorti-Paserini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928–37.CrossRefPubMed

Lin N, Sarantopoulos S, Stone J, Gallinsky I, Stone R, Deangelo D, et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003;102:3455–6.CrossRefPubMed

Cross T, Bagot C, Portmann WJ, Gillet D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol. 2006;81:189–92.CrossRefPubMed

Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mandó OG. Imatinib-induced fatal acute liver failure. World J Gastroenterol. 2007;13:6608–11.CrossRefPubMedPubMedCentral

Thia TJK, Tan HH, Chuah THC, Chow WC, Lui HF. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singap Med J. 2008;49:e86–9.

Perini G, Santos F, Funke V, Ruiz J, Ferraz B, Hamerschlak N. Nilotinib post-liver transplantation for acute hepatic failure related to imatinib. Leuk Res. 2009;33:e234–5.CrossRefPubMed

Martínez Pascual C, Valdés Mas M, de la Peña Moral JM, Miras López M. Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia [in Spanish]. Med Clin (Barc). 2011;137(7):329–30.CrossRef

10.

Tonyali O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N, Benekli M, Buyukberber S. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Med Oncol. 2010;27(3):768–73.CrossRefPubMed

11.

Weise AM, Liu CY, Shields AF. Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine. Ann Pharmacother. 2009;43(4):761–6.CrossRefPubMed

12.

Akamine T, Ando K, Oki E, Saeki H, Nakashima Y, Imamura YU, Ohgaki K, Maehara Y. Acute liver failure due to regorafenib may be caused by impaired liver blood flow: a case report. Anticancer Res. 2015;35(7):4037–41.PubMed

Title: Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report
Authors: Lucas Souto Nacif
Daniel R. Waisberg
Rafael Soares Pinheiro
Fabiana Roberto Lima
Vinicius Rocha-Santos
Wellington Andraus
Luiz Carneiro D’Albuquerque
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Medical Case Reports / Issue 1/2018
Electronic ISSN: 1752-1947
DOI: https://doi.org/10.1186/s13256-018-1588-0

At a glance: The STEP trials

Springer Medicine

Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report

Abstract

Background

Case presentation

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Surgical management of a huge post-circumcision epidermoid cyst of the vulva presenting unusually in a postmenopausal woman: a case report

Significant bleeding from Meckel’s diverticulum after blunt abdominal trauma: a case report

Divergent dislocation of the carpometacarpal joints: a case report

Giant congenital melanocytic nevus in a Cameroonian child: a case report

Composite neuroendocrine carcinoma and squamous cell carcinoma with regional lymph node metastasis: a case report

Correction to: An exotic abscess within the United Kingdom from The Gambia: a case report